Finance

Anjarium Biosciences Raises CHF 55.5M ($61M) Sequence A Financing to Develop Subsequent-Era Non-viral Gene Therapies

– Anjarium’s versatile platform combines proprietary gene vectors, focused non-viral supply applied sciences and environment friendly manufacturing options to unlock the total potential of gene remedy

– Proceeds will likely be utilized for firm development, to broaden its platform and advance its pipeline

– Sequence A co-led by Abingworth and Gimv, alongside Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel firm)

ZURICH, Sept. 16, 2021 /PRNewswire/ — Anjarium Biosciences AG (“Anjarium”), a biotech firm centered on creating and delivering a brand new class of non-viral gene therapies right this moment introduced the closing of a CHF55.5M ($61M) Sequence A financing. The spherical was co-led by Abingworth and Gimv, with important participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel firm).

Anjarium’s revolutionary strategy leverages breakthrough science and experience on the interface of genetic medication, artificial biology and nanoparticle engineering to rationally design and produce tissue-targeted gene therapies, optimized to enhance affected person outcomes in a variety of significant genetic illnesses.

The Firm’s distinctive platform combines proprietary DNA-based gene vectors, pure and artificial nanoparticle supply modalities – together with its novel Hybridosome™ know-how – and cost-efficient, scalable manufacturing options.

By way of this strategy Anjarium has the potential to ship extra predictable, lasting, and inclusionary methods to sort out genetic illness all through a affected person’s lifetime. Additional, this new class of gene remedy gives the chance to handle key shortcomings of present viral gene remedy improvement by creating medicines with diminished immunogenicity, elevated drug payload capability, enhanced focused supply, and individualized a number of dosing.

The proceeds from the Sequence A financing will allow Anjarium to broaden its group, advance its ground-breaking platform and progress a number of therapeutic pipeline packages in direction of scientific improvement.

“As the restrictions of typical viral-vector based mostly gene therapies to ship optimum affected person outcomes develop into more and more evident, a totally non-viral strategy represents an thrilling new therapeutic alternative,” stated Joël de Beer, Founder and CSO of Anjarium Biosciences. “Backed by this syndicate of main buyers, the Anjarium group is trying ahead to persevering with to create and ship options for sufferers past what present gene remedy platforms can handle, tackling extra illnesses, extra exactly and in a extra customized manner.”

Bali Muralidhar, Managing Companion at Abingworth, stated: “Superior therapies comparable to non-viral gene therapies have the potential to supply lifetime advantages to sufferers with genetic illnesses. Anjarium has an thrilling and versatile know-how that presents a broad alternative to boost and lengthen the attain of gene remedy. We sit up for supporting the group to develop its know-how and translate its revolutionary science into life-changing merchandise.”

Bram Vanparys, Companion at Gimv, added: “We’re very excited to assist Anjarium as its groundbreaking science, platform and manufacturing setup holds very excessive potential to vary the best way we strategy gene remedy right this moment – with the chance to ship merchandise with a lot better outcomes and sturdiness.”

Together with Anjarium’s Sequence A financing, Dr. Bali Muralidhar of Abingworth, Dr. Bram Vanparys of Gimv and Dr. Dina Chaya of Omega Funds will be part of the corporate’s Board of Administrators.

About Anjarium Biosciences

Anjarium is targeted on creating a brand new class of non-viral gene therapies to ship extra predictable, enduring, and inclusionary methods to sort out genetic illness all through a affected person’s lifetime. The Firm’s versatile platform goals to leverage breakthrough science and experience on the interface of genetic medication, artificial biology and nanoparticle engineering to generate a pipeline of superior gene therapies with distinctive aggressive benefits over present viral-vector based mostly gene therapies.

Traders in Anjarium embrace main worldwide and strategic buyers Abingworth, Gimv, Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel firm). www.anjarium.com

About Abingworth

Abingworth is a number one transatlantic life sciences funding agency. Abingworth helps rework cutting-edge science into novel medicines by offering capital and experience to prime calibre administration groups constructing world-class corporations. Since 1973, Abingworth has invested in over 175 life science corporations, resulting in 45 M&As and 71 IPOs. Our therapeutic centered investments fall into three classes: seed and early-stage, improvement stage, and scientific co-development. Abingworth helps its portfolio corporations with a group of skilled professionals at workplaces in London, Menlo Park (California), and Boston. www.abingworth.com

About Gimv

Gimv is a European funding firm, listed on Euronext Brussels, with nearly 40 years’ expertise in personal fairness and enterprise capital. The corporate at the moment has a portfolio of EUR 1.1 billion of investments in round 50 portfolio corporations, with mixed turnover of EUR 2.75 billion and 14,000 workers. As a acknowledged market chief in chosen funding platforms, Gimv identifies entrepreneurial, revolutionary corporations with excessive development potential and helps them of their transformation into market leaders. Gimv’s 4 funding platforms are Linked Shopper, Well being & Care, Sensible Industries and Sustainable Cities. Additional info on Gimv might be discovered on www.gimv.com

About Omega Funds

Based in 2004, Omega Funds is a number one worldwide funding agency that creates and invests in life sciences corporations that concentrate on our world’s most pressing medical wants. Omega focuses on figuring out and supporting corporations by worth inflection factors throughout the total arc of innovation, from firm formation by scientific milestones and business adoption. Omega Funds’ portfolio corporations have introduced 39 merchandise to market in a number of therapeutic areas, together with oncology, uncommon illnesses, precision medication and others. Please go to www.omegafunds.com for added info.

Contact:

Anjarium Biosciences
media@anjarium.com

MEDiSTRAVA Consulting
Mark Swallow, George Underwood, Eleanor Perkin
anjarium@medistrava.com

Cision

Cision

View authentic content material:https://www.prnewswire.com/news-releases/anjarium-biosciences-raises-chf-55-5m-61m-series-a-financing-to-develop-next-generation-non-viral-gene-therapies-301377917.html

SOURCE Anjarium Biosciences

Related posts

The beguiling promise of decentralised finance

admin

NIU In the present day | Samantha McCarron goals to demystify Monetary Support as new director

admin

Vaisala updates its technique and raises long-term monetary

admin

Leave a Comment